Stem Cell Therapy for Neurodegenerative Diseases
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">stem-cell-therapy</th>
</tr>
<tr>
<td class="label">Trial</td>
<td>Cell Source</td>
</tr>
<tr>
<td class="label">Kyoto University (Japan)</td>
<td>iPSC-derived DA progenitors</td>
</tr>
<tr>
<td class="label">Bemdaneprocel (BlueRock/Bayer)</td>
<td>hESC-derived DA progenitors</td>
</tr>
<tr>
<td class="label">STEM-PD (Lund/Cambridge)</td>
<td>hESC-derived DA [neurons](/entities/neurons)</td>
</tr>
</table>
Introduction
Overview
Stem cell therapy represents one of the most promising and rapidly advancing therapeutic frontiers for [neurodegenerative [@martineziglesias2025]
/diseases](/diseases)—conditions characterized by the progressive and irreversible loss of specific neuronal populations. Unlike conventional [@chen2024]
pharmacological approaches that aim to modulate symptoms or slow disease progression, stem cell-based strategies offer the theoretical potential to [@takahashi2025]
replace lost [neurons](/entities/neurons), restore disrupted neural circuits, and provide trophic support to surviving cells [@martineziglesias2025] [@bluerock2024]
[@chen2024]. [@lund2024]
Over the past 15 years, more than 76 stem cell therapy trials have been conducted for [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease) alone, with more [@khan2024]
than half occurring in the past five years, reflecting the accelerating pace of translational research in this field [@martineziglesias2025]. [@stoker2020]
The field has been catalyzed by advances in induced pluripotent stem cell (iPSC) technology, which enables the generation of patient-specific or [@neurologylive2024]
donor-matched pluripotent cells from adult somatic cells, circumventing many of the ethical concerns associated with embryonic stem cells. Landmark [@wang2025]
Phase I/II trials in Parkinson's Disease—including the Japanese iPSC-derived dopaminergic neuron trial published in Nature in 2025 [@takahashi2025] [@priest2025]
and BlueRock Therapeutics' bemdaneprocel (hESC-derived) program advancing to Phase III [@bluerock2024]—mark [@barker2017]
a turning point for cell therapy in neurodegeneration, with similar approaches to Alzheimer's Disease and [amyotrophic lateral sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis) also [@kim2024]
showing early signs of promise.
Types of Stem Cells Used in Neurodegeneration Research
Embryonic Stem Cells (ESCs)
Embryonic stem cells are derived from the inner cell mass of blastocysts and possess unlimited self-renewal capacity and the ability to differentiate
into any cell type (pluripotency). Human ESCs (hESCs) have been used to generate high-purity populations of dopaminergic [neurons](/entities/neurons), motor [neurons](/entities/neurons),
and other neural cell types for transplantation studies [@chen2024].
The most advanced clinical programs using hESC-derived cells include:
- Bemdaneprocel (BRT-DA01): BlueRock Therapeutics' hESC-derived dopaminergic progenitor program for Parkinson's Disease, now in Phase III [@bluerock2024]
- STEM-PD: A European first-in-human trial of hESC-derived dopaminergic [neurons](/entities/neurons) for Parkinson's Disease [@lund2024]
Ethical concerns regarding embryo destruction and the requirement for immunosuppression in allogeneic transplantation remain important considerations
[@khan2024].
Induced Pluripotent Stem Cells (iPSCs)
iPSCs are generated by reprogramming adult somatic cells (typically skin fibroblasts or blood cells) to a pluripotent state through expression of
defined transcription factors (Oct4, Sox2, Klf4, c-Myc). iPSC technology, pioneered by Shinya Yamanaka in 2006, enables the creation of
patient-specific pluripotent cells without embryo destruction [@martineziglesias2025].
Key advantages of iPSCs:
- Autologous transplantation potential: Patient-derived iPSCs could theoretically be transplanted without immunosuppression
- Disease modeling: iPSCs from patients with genetic neurodegenerative diseases enable the study of disease mechanisms in vitro
- Drug screening: Patient-specific iPSC-derived [neurons](/entities/neurons) serve as platforms for personalized drug testing
The Japanese iPSC-derived dopaminergic neuron trial, published in
Nature in April 2025, demonstrated that allogeneic iPSC-derived dopaminergic
progenitors survived in the brains of patients with Parkinson's Disease, produced [dopamine](/entities/dopamine), and did not form tumors, establishing safety and
suggesting potential clinical benefit [@takahashi2025].
Mesenchymal Stem Cells (MSCs)
MSCs are multipotent stromal cells found in bone marrow, adipose tissue, umbilical cord blood, and other tissues. While MSCs have limited capacity to
differentiate into functional [neurons](/entities/neurons), they exert neuroprotective effects primarily through paracrine mechanisms [@chen2024]:
- Secretion of neurotrophic factors ([BDNF](/proteins/bdnf-protein), GDNF, NGF, VEGF)
- Anti-inflammatory modulation of [microglia](/cell-types/microglia)/entities/microglia, and [oligodendrocytes](/entities/oligodendrocytes). Both endogenous NSCs and transplanted exogenous NSCs have been investigated for neurodegenerative applications [@chen2024].
Applications by Disease
Parkinson's Disease
Parkinson's Disease is the most advanced application of stem cell therapy in neurodegeneration, owing to the relatively focal nature of the primary
pathology—loss of dopaminergic [neurons](/entities/neurons) in the [substantia nigra](/brain-regions/substantia-nigra) pars compacta. The concept of cell replacement for Parkinson's Disease was
validated in the 1980s–1990s by fetal ventral mesencephalic tissue transplantation studies, which demonstrated that transplanted dopamine [neurons](/entities/neurons)
could survive, reinnervate the striatum, and improve motor symptoms in some patients [@stoker2020].
Current Clinical Trials:
The bemdaneprocel Phase I trial (12 patients) showed particularly encouraging results: high-dose recipients demonstrated a mean 21.9-point reduction
in the Unified Parkinson's Disease Rating Scale (UPDRS) Part III motor score compared with baseline, with good tolerability and no serious
drug-related adverse events at 24 months post-surgery. The 24-month follow-up data were published in Nature (2025), confirming graft survival
via PET imaging. The program is now advancing to a randomized, sham surgery-controlled Phase III trial with
approximately 102 patients [@bluerock2024].
Alzheimer's Disease
Stem cell therapy for Alzheimer's Disease faces unique challenges because the pathology is diffuse, affecting multiple brain regions and cell types.
Unlike Parkinson's Disease, Alzheimer's does not involve the loss of a single defined neuronal population but rather a widespread degeneration driven
by [amyloid-beta](/proteins/amyloid-beta) plaques, tau] tangles, [neuroinflammation](/mechanisms/neuroinflammation), and [synaptic dysfunction](/mechanisms/synaptic-dysfunction) [@martineziglesias2025].
Current approaches focus on:
MSC-mediated neuroprotection: Intravenous or intrathecal MSC administration to modulate neuroinflammation and provide trophic support
NSC transplantation: Direct injection of neural stem cells into affected brain regions to restore cholinergic circuits
Autologous adipose-derived stem cells: The first-in-human Phase I trial by Regeneration Biomedical (RB-ADSC) began dosing patients in March
2024, delivering autologous stem cells directly into the ventricular system to bypass the [blood-brain barrier](/entities/blood-brain-barrier) [@neurologylive2024]
Preclinical studies in transgenic Alzheimer's mouse models have shown that MSC transplantation can reduce amyloid plaque burden (potentially through
enhanced microglial phagocytosis), decrease neuroinflammatory markers, promote [autophagy](/mechanisms/autophagy-lysosome-neurodegeneration)-mediated clearance, and improve cognitive performance in
behavioral assays [@martineziglesias2025].
Amyotrophic Lateral Sclerosis (ALS)
ALS involves the progressive loss of upper and lower motor [neurons](/entities/neurons), presenting both challenges and opportunities for cell therapy. Current stem cell
approaches for ALS include [@chen2024]:
- Motor neuron replacement: iPSC-derived motor neurons transplanted into the spinal cord
- Astrocyte transplantation: Healthy [astrocytes](/cell-types/astrocytes) to replace disease-associated reactive [astrocytes](/cell-types/astrocytes) and restore glutamate buffering
- MSC neuroprotection: Intrathecal MSC delivery for trophic support and anti-inflammatory effects
- Neural progenitor cells: Intraspinal injection of NSCs to provide [BDNF](/proteins/bdnf-protein) and other growth factors
Clinical trials include NurOwn (MSC-NTF cells, autologous MSCs engineered to secrete neurotrophic factors), which showed mixed results in Phase III.
Huntington's Disease
[Huntington's disease](/mechanisms/huntington-pathway) involves the progressive degeneration of GABAergic medium spiny neurons in the striatum. Fetal striatal tissue transplantation
was tested in clinical trials in the early 2000s with variable results. Current approaches focus on iPSC-derived GABAergic neurons and MSC-mediated
neuroprotection [@chen2024].
Multiple Sclerosis
For [multiple sclerosis](/diseases/multiple-sclerosis), stem cell strategies focus on remyelination through transplantation of oligodendrocyte progenitor cells, as well as autologous hematopoietic stem cell transplantation (aHSCT) to "reset" the immune system. aHSCT has shown remarkable efficacy in aggressive relapsing-remitting MS, with some patients achieving long-term disease-free status.
Challenges and Limitations
Cell Survival and Integration
A major challenge is ensuring that transplanted cells survive the hostile microenvironment of the diseased brain, integrate into existing circuits,
and form functional synaptic connections. Cell survival rates in early transplantation studies have often been low (5–20%), though optimized protocols
and co-transplantation with supportive factors have improved outcomes [@stoker2020].
Tumorigenicity
The pluripotent nature of ESCs and iPSCs raises concerns about teratoma formation from residual undifferentiated cells. Rigorous differentiation
protocols, cell sorting, and extended in vitro maturation are employed to minimize this risk. To date, no tumor formation has been reported in
clinical trials using highly purified neural progenitors [@takahashi2025].
Immunological Considerations
Allogeneic stem cell transplants require immunosuppressive therapy to prevent graft rejection. Autologous iPSC-derived cells could theoretically
circumvent this requirement, but the lengthy and costly reprogramming and differentiation process for individual patients presents logistical
challenges. "Off-the-shelf" approaches using HLA-matched or HLA-engineered universal donor cells are being developed to balance immunocompatibility
with scalability [@khan2024].
Delivery Methods
Optimal delivery of stem cells to the central nervous system remains challenging:
- Intracerebral injection: Direct but invasive, requiring stereotactic neurosurgery
- Intrathecal injection: Delivery into cerebrospinal fluid, less invasive but variable cell distribution
- Intravenous infusion: Non-invasive but limited by [blood-brain barrier](/entities/blood-brain-barrier) crossing and trapping in peripheral organs (lungs, liver)
- Intraventricular injection: Delivery into brain ventricles for broader CSF distribution
Disease-Specific Challenges
Each neurodegenerative disease presents unique challenges for cell therapy:
- Alzheimer's Disease: Diffuse pathology requires widespread cellular effects
- ALS: Need for both upper and lower motor neuron replacement across brain and spinal cord
- Huntington's Disease: Transplanted cells may be susceptible to the same mutant [huntingtin](/proteins/huntingtin) protein toxicity
- Prion diseases: Risk of prion infection of transplanted cells
Emerging Technologies
CRISPR-Enhanced Stem Cell Therapy
Combining gene editing with stem cell technology offers new possibilities [@wang2025]:
- Correction of disease-causing mutations in patient-derived iPSCs before transplantation
- Engineering of stress-resistance genes into donor cells
- Knockout of genes that make transplanted cells susceptible to disease pathology
- Creation of "universal donor" cells with reduced immunogenicity
Organoid-Based Approaches
Brain organoids—three-dimensional structures grown from stem cells that recapitulate aspects of brain architecture—are being explored both as research tools and potential therapeutic modalities. Organoid transplantation may provide more physiologically organized tissue grafts compared with dissociated cell suspensions.
Exosome and Secretome Therapies
An emerging approach uses the secreted factors (secretome) or extracellular vesicles ([exosomes) from stem cells rather than the cells themselves. This "cell-free" approach may retain many of the paracrine benefits of stem cell therapy while avoiding risks associated with cell transplantation.
Clinical Landscape (2025)
As of 2025, the global clinical trial landscape for stem cell therapy in neurodegeneration includes [@priest2025]00445-4):
- Parkinson's Disease: 13 approved trials, with bemdaneprocel advancing to Phase III
- Alzheimer's Disease: 27 total trials conducted, most using MSCs
- ALS: Multiple trials with MSCs, NSCs, and iPSC-derived motor neurons
- Total patients dosed: >1,200 patients with human pluripotent stem cell products
- Cumulative cells administered: >10^11 cells
- Generalizable safety concerns: None identified to date
See Also
- [Neurodegenerative Drug Development Pipeline](/clinical-trials/drug-pipeline)
- [Deep Brain Stimulation (DBS)](/therapeutics/deep-brain-stimulation)
- [Gene Therapy for Neurodegenerative Diseases](/therapeutics/gene-therapy)
Background
The study of Stem Cell Therapy For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
- [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
- [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data
References
Martinez-Iglesias, O., et al., (2025). Stem cells strike back: advancements in Alzheimer's and Parkinson's Disease treatment and modeling efforts from 2019 to 2024. Journal of Molecular Medicine. [PMC12701875 (2025)
Chen, S., et al., (2024). Stem cell therapies for neurological disorders: current progress, challenges, and future perspectives. European Journal of Medical Research, 29, 516. [Springer (2024)
Takahashi, J., et al., (2025). Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson's Disease. Nature. [doi:10.1038/s41586-025-08700-0 (2025)
Unknown, BlueRock Therapeutics. (2024). BlueRock Therapeutics advances investigational cell therapy bemdaneprocel for treating Parkinson's Disease to registrational Phase III clinical trial. [BlueRock Press Release (2024)
Unknown, Lund University. (2024). Update on STEM-PD clinical trial – stem cell-based transplant for Parkinson's Disease. [Lund University (2024)
Khan, A., et al., (2024). Recent advances in stem cell therapy: efficacy, ethics, and future perspectives. International Journal of Surgery, 110(10), 6555–6571. [LWW (2024)
Unknown, Stoker, T.B., & Barker, R.A. (2020). Current status and future perspectives on stem cell-based therapies for Parkinson's Disease. Journal of Clinical Medicine, 9(3), 689. [PMC9978267 (2020)
Unknown, NeurologyLive. (2024). Patient dosing commenced in Phase 1 study of Regeneration's stem cell therapy for Alzheimer's Disease. [NeurologyLive (2024)
Wang, X., et al., (2025). Stem cell and CRISPR/Cas9 gene editing technology in Alzheimer's Disease therapy. Frontiers in Genome Editing, 7, 1612868. [Frontiers (2025)
Priest, C.A., et al., (2025). Pluripotent stem-cell-derived therapies in clinical trial: A 2025 update. Cell Stem Cell, 32(1), 29–51. [Cell Press (2025)
[Barker, R.A., et al., (2017). Cell-based therapies for Parkinson disease—past insights and future potential. Nature Reviews Neurology, 13(2), 87–98. [DOI (2017)](https://doi.org/10.1038/nrneurol.2016.170)
Kim, J., et al., (2024). Stem cell therapy in Alzheimer's Disease: current status and perspectives. Free Radical Biology and Medicine, 225, 10–24. [PMC11618239 (2024)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
- [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
- [Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: GLP1R, BDNF
- [Partial Neuronal Reprogramming via Modified Yamanaka Cocktail](/hypothesis/h-baba5269) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: OCT4
- [Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — <span style="color:#ffd54f;font-weight:600">0.48</span> · Target: CHR2/BDNF
- [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
- [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
- [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
Related Analyses:
- [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
- [Senolytic therapy for age-related neurodegeneration](/analysis/SDA-2026-04-01-gap-013) 🔄
- [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
- [Epigenetic clocks and biological aging in neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-bc5f270e) 🔄